Clinical trial
Edrecolomab in Treating Patients With Stage II Colon Cancer
NCT00002968 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00002968 |
|---|---|
| Title | Edrecolomab in Treating Patients With Stage II Colon Cancer |
| Official title | Phase III Randomized Study of Adjuvant Immunotherapy With Monoclonal Antibody 17-1A Versus No Adjuvant Therapy Following Resection for State II (Modified Astler-Coller B2) Adenocarcinoma of the Colon |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Mucinous Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Colon, Stage IIA Colon Cancer, Stage IIB Colon Cancer, Stage IIC Colon Cancer |
| Intervention type | Biological, Other |
| Interventions | edrecolomab, laboratory biomarker analysis |
| Enrollment | 2,100 |
| Start date | May 1, 1997 |
| Primary completion | Jul 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 29, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: